List I | List II | ||
---|---|---|---|
A | Grignard reagent | I | R2CuLi |
B | Gilman reagent | II | RMgX |
C | Benzyne mechanism | III | 2 molecules of CH3CHO |
D | Aldol condensation | IV | SNAr |
Ingrediant | Function | Table A | Table B | Table C | Table D | ||
A | Aceta- minophen | I | Drug | 300 mg | - | 300 mg | 300 mg |
B | Aspirin | II | Drug | - | 300 mg | - | - |
C | Lactose | III | Filler | 100 mg | 100 mg | - | 100 mg |
D | Avicel | IV | Filler | - | - | 100 mg | - |
starch | Dis-integrant | 50 mg | 50 mg | - | 50 mg | ||
Avicel | Dis-integrant | - | - | 50 mg | - | ||
Magsterate | Lubricant | 2 mg | 2 mg | 2 mg | 2 mg | ||
Gelatin | Binder | 10 mg | 10 mg | 10 mg | 10 mg |
List I | List II | ||
---|---|---|---|
A. | Lamivudine | I. | Integrase inhibitors |
B. | Efavirenz | II. | Protease inhibitors |
C. | Ritonavir | III. | Nucleoside reverse transcriptase inhibitors |
D. | Raltegravir | IV. | Non-nucleoside reverse transcriptase inhibitors. |
List I | List II | ||
---|---|---|---|
A. | Aminoglycosides | I. | Hearing loss, kidney damage |
B. | Tetracyclines | II. | Neurological and renal toxicity |
C. | Vancomycin | III. | 8th cranial nerve and kidney toxicity |
D. | Polymyxin B | IV. | Liver and kidney damage, anti anabolic effect |